R&D | November 17, 2025
SPARC announces consolidation of R&D laboratories and facilities
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
This is the first drug to receive a recommendation for this preventative indication in the European Union
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Subscribe To Our Newsletter & Stay Updated
